l e t t e r s Bosma arhinia microphthalmia syndrome (BAMS) is an extremely rare and striking condition characterized by complete absence of the nose with or without ocular defects. We report here that missense mutations in the epigenetic regulator SMCHD1 mapping to the extended ATPase domain of the encoded protein cause BAMS in all 14 cases studied. All mutations were de novo where parental DNA was available. Biochemical tests and in vivo assays in Xenopus laevis embryos suggest that these mutations may behave as gain-of-function alleles. This finding is in contrast to the loss-of-function mutations in SMCHD1 that have been associated with facioscapulohumeral muscular dystrophy (FSHD) type 2. Our results establish SMCHD1 as a key player in nasal development and provide biochemical insight into its enzymatic function that may be exploited for development of therapeutics for FSHD.
Congenital absence of the nose (arhinia) is a rare and striking condition with fewer than 50 patients reported thus far 1 . Arhinia is variably associated with absent paranasal sinuses, hypertelorism, microphthalmia, colobomas, nasolacrimal duct abnormalities, midface hypoplasia, high-arched palate, absent olfactory bulbs and defects of the reproductive axis in males. In its most severe presentation, consisting of nasal, ocular and reproductive defects, it is referred to as BAMS (MIM 603457) 1, 2 . Arhinia is presumed to result from a specific defect in the nasal placodes or surrounding neural crest-derived tissues during embryonic development, but a genetic cause has not been established.
We investigated 14 unrelated individuals with isolated arhinia or a syndromic presentation compatible with BAMS ( Fig. 1a-l,  Supplementary Fig. 1 and Supplementary Table 1) . Trio or quartet whole-exome sequencing for cases 1, 2 and 9-12 led to the identification of de novo heterozygous missense mutations in the SMCHD1 gene (encoding structural maintenance of chromosomes flexible hinge domain containing 1; NM_015295.2) in all six cases (Fig. 1m , Table 1 and Supplementary Table 2 ), which were confirmed by Sanger sequencing (Supplementary Fig. 2 ). Singleton whole-exome sequencing for case 13 also identified an SMCHD1 mutation. We then performed Sanger sequencing of SMCHD1 in the seven remaining patients with BAMS. Heterozygous missense mutations were identified in all. In total, 11 of the 14 variants were de novo, suggesting germline mutations in parental gametes, while in three cases parental DNA was not available ( Table 1 and Supplementary Fig. 2) . None of the identified mutations have been reported in the Exome Aggregation Consortium (ExAC), Exome Variant Server (EVS) or dbSNP144 database (accessed via the UCSC Genome Browser, November 2016), all mutations affected highly conserved residues (Supplementary Fig. 3 ) and all were predicted to be damaging by PolyPhen-2 ( Table 1 ). All 14 mutations are located in exons 3, 8-10, 12 or 13 of SMCHD1 (48 exons in total); these exons encode the ATPase domain of SMCHD1 and an associated region immediately C terminal to it. Notably, 6 of the 14 patients had mutations that affected three adjacent amino acidsAla134, Ser135 and Glu136-while p.His348Arg and p.Asp420Val were identified in three and two independent patients each, suggesting possible mutational hotspots (Fig. 1m) . Mutations in SMCHD1 in individuals with arhinia have also been identified in an independent study that included six of the cases analyzed here (cases 2, 4-7 and 13; see the accompanying manuscript 3 ).
During craniofacial development, the olfactory placode ectoderm thickens and invaginates to form the olfactory epithelium within the nasal cavity, a process that depends on crosstalk between the placodal De novo mutations in SMCHD1 cause Bosma arhinia microphthalmia syndrome and abrogate nasal development l e t t e r s epithelium and the underlying cranial neural crest-derived mesenchyme 4 . For example, ablation of the nasal placode epithelium in chick embryos disrupts the development of adjacent nasal skeletal elements 5 . We observed strong X-gal (5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside) staining in the developing face of mouse embryos expressing lacZ from the Smchd1 locus 6 , including in the nasal placodes and optic vesicles at embryonic day (E) 9.5 and in the nasal epithelium at E12.5 ( Supplementary Fig. 4 ). Eurexpress in situ hybridization data indicate regional expression of Smchd1 in the nasal cavity in E14.5 mice, while transcriptional profiling of postnatal olfactory epithelium demonstrated that Smchd1 is specifically expressed in immature olfactory sensory neurons 7 . These data are consistent with roles for SMCHD1 during early nasal development. Gonadotropin-releasing hormone (GnRH) neurons migrate from the olfactory placode along olfactory axon tracts to the hypothalamus, where they regulate reproductive hormone release from the pituitary gland. Defects in the reproductive axis have occasionally been reported in males with arhinia 1,2,8 ; we confirm this finding and (i-l) Case 11, with a forehead implant (rectangular box) in preparation for rhinoplasty (j), 6 months after the operation (k) and in a computed tomography scan of the skull before the operation (l). Consent was obtained to publish patient images. (m) Positions of BAMS-associated missense variants (black) and heterozygous loss-of-function variants from ExAC (red) in SMCHD1. Short bars represent known missense (purple) and frameshift or nonsense (red) FSHD2-associated variants. See supplementary Figure 3 for details on the exact amino acids mutated in FSHD2 in the N-terminal region. l e t t e r s also report pubertal delay or anomalies of menarche in all three post-pubertal females in our series (Supplementary Table 1 ). The reproductive axis defects associated with arhinia are likely secondary to a defect in GnRH neuron production in or migration from the olfactory placode.
Smchd1 was identified as a modifier of transgene silencing in mice and was subsequently shown to be involved in X-chromosome inactivation, where it is required for CpG island (CGI) methylation on the inactive X chromosome, CGI-independent silencing of some X-chromosome genes and compaction of the inactive X chromosome 6,9-11 . In addition, Smchd1 functions as an epigenetic repressor at various autosomal loci, with dysregulation of imprinted and monoallelically expressed gene clusters observed in mice mutant for Smchd1 10, 12, 13 . A requirement for SMCHD1 in the repair of DNA double-strand breaks has also been demonstrated 14, 15 . Whereas female mice null for Smchd1 display midgestation lethality due to derepression of genes on the inactive X chromosome, male mutant mice display perinatal lethality of undescribed causes in certain strains or viability on the FVB/n background 12 . Strikingly, craniofacial abnormalities have not been documented in mice with Smchd1 loss of function regardless of their sex.
Recently, haploinsufficiency for SMCHD1 was reported as a cause of FSHD type 2 (FSHD2; MIM 158901) 16 . FSHD has a prevalence of 1 in 20,000, with FSHD type 1 (FSHD1) and FSHD2 accounting for ~95% and ~5% of cases, respectively 17 . FSHD results from pathogenic misexpression of the transcription factor DUX4 (encoded by an array of D4Z4 repeats on chromosome 4q) in skeletal muscle. In FSHD1 (MIM 158900), D4Z4 repeat contraction leads to hypomethylation of the locus and derepression of DUX4 expression on a permissive haplotype (4qA) that harbors a stabilizing polyadenylation signal for DUX4 mRNA 17, 18 . FSHD2 occurs in individuals harboring loss-of-function SMCHD1 mutations and the permissive 4qA allele, without the requirement for D4Z4 repeat contraction, although SMCHD1 mutations can also modify the severity of FSHD1 (refs. 16,19) . SMCHD1 is thought to function as a silencer at the 4q locus via binding to the D4Z4 repeats 16 . Over 80 unique, putatively pathogenic SMCHD1 variants have been reported in patients with FSHD2 (LOVD SMCHD1 variant database; see URLs). These mutations, which include clear loss-of-function alleles, map throughout the protein and are not clustered in specific domains. Several loss-offunction mutations have also been reported in the ExAC database (Fig. 1m) , and over 60 deletions affecting SMCHD1 have been reported in the DECIPHER database (available phenotypic information does not indicate occurrence of arhinia in deletion carriers). We analyzed the methylation status of D4Z4 repeats in peripheral blood leukocytes from patients with BAMS by sodium bisulfite sequencing ( Supplementary Figs. 5-7 and Supplementary Table 3) . Although a trend for hypomethylation was noted for patients with BAMS relative to controls or their unaffected family members, depending on the site tested within the D4Z4 repeat, some patients with BAMS were normally methylated. A large variability in D4Z4 methylation has also been observed in controls and patients with FSHD 20 , and altered methylation is not an absolute indicator of FSHD. Moreover, an important argument against BAMS-and FSHD2-associated mutations acting in the same direction is the absence in the literature (to our knowledge) of reports of BAMS and FSHD co-occurring in the same patient. None of the patients with BAMS reported here have signs of muscular dystrophy, including both the individuals (cases 2 and 12) older than the average age of onset for FSHD2 of 26 years 21 , and none of the BAMS-associated missense mutations identified here have been linked to FSHD2.
Proteins of the SMC family are involved in chromatid cohesion, condensation of chromosomes and DNA repair. SMCHD1 is considered to be a non-canonical member of the family, with a C-terminal chromatin-binding hinge domain and an N-terminal GHKL (gyrase, Hsp90, histidine kinase and MutL) ATPase domain 22 (Fig. 1m) . SMCHD1 may potentially use energy obtained from ATP hydrolysis to manipulate chromatin ultrastructure and interactions. Using small-angle X-ray scattering, the purified recombinant mouse Smchd1 ATPase domain and an adjacent C-terminal region (amino acids 111-702 for the two regions combined; denoted N-terminal region in Fig. 1m ) have been shown to adopt a structural conformation similar to that of Hsp90 (ref. 22) . Consistent with this, the Hsp90 inhibitor radicicol decreases the ATPase activity of Smchd1 (refs. 22,23) . Mapping of the SMCHDI amino acids mutated in BAMS and FSHD2 to the homology model of Smchd1 on the basis of the Hsp90 crystal structure indicates that the major cluster of variants in BAMS (amino acids 134-136) is situated immediately N terminal to motif I, which is highly conserved among the GHKL ATPases and participates in coordination of the Mg 2+ -ATP complex during ATP hydrolysis 24 ( Supplementary Figs. 3 and 8) . The finding of other BAMS-associated mutations that map to the region immediately C terminal to the ATPase domain supports the idea that this extended Fig. 9 ), we hypothesized that the mutations in BAMS might result in a gain rather than a loss of function for the SMCHD1 protein.
To test this hypothesis, we conducted ATPase assays using the purified recombinant N-terminal region of mouse Smchd1 harboring BAMS-or FSHD2-associated alterations. In comparison to wild-type protein, the N-terminal region containing the p.Ala134Ser, p.Ser135Cys or p.Glu136Gly substitution had increased protein hydrolysis of ATP, whereas the FSHD2 substitutions p.Tyr353Cys 16 and p.Thr527Met 19 resulted in strongly and slightly decreased ATPase activity, respectively; activity was unchanged with the BAMS-associated substitution p.Asp420Val (Fig. 2) . The half-maximal inhibitory concentration (IC 50 ) of radicicol was similar for the ATPase activities of the BAMS-associated mutant and wild-type recombinant proteins ( Supplementary  Fig. 10 ), suggesting that the mutants retain an intact ATP-binding site. These results suggest that BAMS-associated mutations increase the catalytic activity of SMCHD1.
We next sought to validate these biochemical results in vivo using full-length SMCHD1 protein. In Xenopus, the expression of smchd1 begins zygotically and increases steadily after gastrulation (Fig. 3a) . Endogenous smchd1 expression is strongly enriched in the head region and the neural tube (Fig. 3b) . To faithfully recapitulate this expression pattern, the two dorsal-animal blastomeres of eight-cell-stage Xenopus embryos were microinjected with 120 pg of capped mRNA encoding either wild-type or mutant human SMCHD1 (Fig. 3c) . Each set of injected embryos was checked to ensure expression of human SMCHD1 protein ( Fig. 3g and Supplementary Fig. 11 ). Only tadpoles overexpressing SMCHD1 mRNA with BAMS-associated mutations showed noticeable craniofacial anomalies ( Fig. 3d-f and Supplementary Fig. 12 ), including microphthalmia and, in severe cases, anophthalmia (Fig. 3f, right) . At 4 days post-fertilization (d.p.f.), quantification of eye size showed a marked reduction in the diameter of the eye in tadpoles overexpressing BAMS-associated mutants, whereas tadpoles overexpressing wild-type SMCHD1 or Tyr353Cys SMCHD1, an FSHD2-associated mutant, were indistinguishable from control, uninjected embryos (Fig. 3h) . One of the BAMS-associated mutants with phenotypic effects in this assay, Asp420Val, showed no change in ATPase activity in vitro (Fig. 2) , suggesting that the in vivo assay has higher sensitivity. Whole-mount in situ hybridization showed a decrease in the size of the eye and nasal placodes, marked by rx2a and six1 expression, respectively, upon overexpression of a BAMS-associated mutant (Fig. 3i,j) . In contrast, migration of cranial neural crest, marked by twist1 expression, was largely unaffected. Development of craniofacial anomalies was dose dependent in injections with wild-type SMCHD1 or a BAMS-associated mutant, whereas overexpression of the FSHD2 mutant Tyr353Cys did not have an effect, regardless of dose ( Fig. 3k and Supplementary Fig. 12 ). The finding that wild-type SMCHD1, when overexpressed at a sufficiently high concentration, acts in the same phenotypic direction as the BAMS-associated mutants suggests that these mutants may, at least in part, act by augmenting the normal activity of the protein. These in vivo results, which partially recapitulate the microphthalmia and facial hypoplasia seen in human patients with severe BAMS, further support the notion that, in contrast to FSHD2 alleles, BAMS-associated missense mutations may exhibit gain-of-function or neomorphic activity. We have not formally excluded the possibility that BAMS-associated mutants may behave as dominant negatives through heterodimerization with wild-type protein. However, we believe that this is unlikely, given the effects described above for overexpressed wild-type SMCHD1 and the finding that the isolated ATPase domain containing BAMS-associated variants can increase ATPase activity by itself (Fig. 2) . In addition, a human phenotype associated with a dominant-negative mutation would be expected to present as a more severe disease than that associated with haploinsufficiency of the same gene, with at least some phenotypic overlap, but this is not the case for BAMS and FSHD. The amount of ADP produced by the mutant proteins was normalized to that produced by wild-type protein at each protein and substrate concentration as in a-e. Normalized values are plotted as the means ± s.d. from two independent experiments (n = 44 for Ala134Ser, n = 24 for Ser135Cys, n = 32 for Glu136Gly, Asp420Val, Tyr353Cys and Thr527Met). In addition to analyzing normalized fold changes, for each mutant, the mean of the triplicate measures at each protein and ATP concentration was compared to that for wild-type protein using the Wilcoxon matched-pairs signed-rank test; apart from Asp420Val with P = 0.1776 (non-significant), all other mutants were different from wild-type protein at P < 0.0001 (significant).
l e t t e r s
In conclusion, we have identified de novo missense mutations restricted to the extended ATPase domain of SMCHD1 as the cause of isolated arhinia and BAMS. It will be of great interest to explore the epistatic relationships between SMCHD1 and known regulators of nasal development, such as the PAX6 protein and fibroblast growth factor (FGF) and bone morphogenetic protein (BMP) signaling 2 , as well as to uncover other potential human-specific nasal regulators.
Nose shape and size vary greatly across human populations and even more drastically among animal species, with the elephant's trunk being an extreme example. As such, it will be interesting to determine the role of SMCHD1 in controlling nose size from an evolutionary perspective.
Given that loss-of-function mutations in SMCHD1 are associated with FSHD2, BAMS and FSHD2 represent a rare example of different l e t t e r s functional classes of mutations in the same gene leading to vastly different human disorders, in terms of the affected tissue and age of onset. As FSHD is caused in part by loss of SMCHD1, the development of drugs that augment the expression or activity of SMCHD1 in affected muscles as a form of treatment is currently being pursued (for example, by Facio Therapies; see URLs). Our identification of ATPaseactivity-augmenting mutations in SMCHD1 may inform gene therapy approaches or, in combination with future structural studies on the effect of these mutations on the ATPase domain, aid the design of drugs that induce SMCHD1 gain of function, for treatment of FSHD. Importantly, for such an approach, the deleterious consequences of BAMS-associated SMCHD1 mutations seem to be restricted to a narrow window of human embryonic development. 
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Subjects. In all cases, informed consent was obtained from the families for genetic testing. For patients in Figure 1 , consent to publish photographs was obtained.
Whole-exome sequencing. Whole-exome sequencing was conducted in accordance with approved institutional ethical guidelines (Comité de Protection des Personnes Ile-de-France II; Ethics Committee of the University Hospital Cologne, Germany; National University of Singapore Institutional Review Board). For trio whole-exome sequencing of case 1, Agilent SureSelect libraries were prepared using 3 µg of genomic DNA from each individual and sheared with a Covaris S2 Ultrasonicator. Exome capture was performed with 51Mb SureSelect Human All Exon kit v5 (Agilent Technologies). Sequencing was carried out on a pool of barcoded exome libraries using a HiSeq 2500 instrument (Illumina), generating 100 + 100 bp paired-end reads. After demultiplexing, paired-end sequences were mapped to the reference human genome (GRCh37/hg19 assembly, NCBI) using Burrows-Wheeler aligner (BWA). The mean depth of coverage obtained for the three samples from case 1 was 123-fold, 149-fold and 150-fold, and 98% of the exome was covered by at least 15-fold. Downstream processing was performed using the Genome Analysis Toolkit (GATK) 25 , SAMtools 26 and Picard. Variant calls were made with the GATK UnifiedGenotyper. All calls with read coverage ≤2-fold or a Phred-scaled SNP quality score of ≤20-fold were removed from consideration. Variant annotation was based on Ensembl release 71 (ref. 27 ). Variants were filtered against publicly available SNPs plus variant data from more than 7,000 in-house exomes (Institut Imagine).
For trio whole-exome sequencing of case 2, exonic and adjacent intronic sequences were enriched from genomic DNA using the NimbleGen SeqCap EZ Human Exome Library v2.0 enrichment kit and probes were run on an Illumina HiSeq 2000 sequencer at the Cologne Center for Genomics (CCG). Data analysis and filtering of mapped target sequences were performed with 'Varbank' exome and genome analysis pipeline v.2.1 (CCG), and data were filtered for high-quality (coverage of more than 6 reads, minimum quality score of 10), rare (MAF < 0.5%) autosomal recessive and de novo variants.
For trios of cases 9 and 11 and quartets of cases 10 and 12, whole-exome sequencing was performed at the Genome Institute of Singapore. Barcoded libraries were prepared for each individual by shearing 1 µg of genomic DNA, followed by end repair, A-tailing, adaptor ligation and PCR enrichment, and libraries were then pooled and hybridized with NimbleGen SeqCap EZ Human Exome Library v3.0 probes. Captured DNA targets were purified and PCR amplified, and were then sequenced on Illumina HiSeq 2500 (cases 9 and 11) or HiSeq 4000 (cases 10 and 12) sequencers. Variant calling was performed according to the recommended best practices of GATK (v3.4.46). Reads were mapped to GRCh37/hg19 using BWA, and the aligned files were preprocessed by Picard and GATK 25, 28, 29 . All samples were sequenced with mean coverage of 75× or higher. Variants were called using GATK HaplotypeCaller along with in-house exomes sequenced with the same chemistry. Variants were recalibrated, annotated and filtered against in-house data plus common publicly available databases. Each family was analyzed independently using Phen-Gen 30 for de novo and recessive disease inheritance patterns. Variants with alternate allele frequency of ≤10 reads or total coverage of ≤20 reads were not considered.
For whole-exome sequencing of case 13, a library was prepared using the SureSelect XT Human All Exon v5 kit (Agilent Technologies) according to the manufacturer's instructions, followed by sequencing on a HiSeq 2500 (Illumina) sequencer. Raw data files were converted to fastq files with bcl2fastq software package version 1.8.4 (Illumina). fastq files were mapped by Novoalign version 3 (Novocraft) to the hg19 human reference genome sequence. In this step, singlenucleotide variant (SNV) information in dbSNP 31 build 138 was used for base quality score recalibration. Marking of PCR duplicates and position-wise sorting were performed with Novosort version 3 (Novocraft). Calling of SNVs and small indels was performed using GATK 25,28,29 version 3.4-46. A GATK workflow 32 was used in which local realignment and variant calling were performed by IndelRealigner and HaplotypeCaller, respectively. Low-quality calls for SNVs and small indels were removed it they met the following criteria: QD < 2.0, MQ < 40.0, FS > 60.0, MQRankSum < −12.5 or ReadPosRankSum < −8.0 for SNVs; QD < 2.0, ReadPosRankSum < −20.0 or FS > 200.0 for small indels. SNVs and small indels were annotated with the ANNOVAR software package 33 using the following data sets and programs: gene information from DNA methylation analysis. DNA methylation was analyzed at single-base resolution after sodium bisulfite modification, PCR amplification, cloning and Sanger sequencing. Briefly, 2 µg of genomic DNA was denatured for 30 min at 37 °C in 0.4 N NaOH and incubated overnight in a solution of 3 M sodium bisulfite (pH 5) and 10 mM hydroquinone using a previously described protocol 40 . Converted DNA was then purified using the Wizard DNA CleanUp kit (Promega) following the manufacturer's recommendations and precipitated by ethanol precipitation for 5 h at −20 °C. After centrifugation, DNA pellets were resuspended in 20 µl of water and stored at −20 °C until use. Converted DNA was then amplified using primer sets (Supplementary Table 4 ) designed with MethPrimer software 41 , avoiding the occurrence of CpGs in primer sequences to allow amplification of methylated and unmethylated DNA with the same efficiency. Amplification was carried out using High-Fidelity Taq polymerase (Roche) according to the manufacturer's instructions. After initial denaturation at 94 °C for 2 min, amplification was carried out at 94 °C for 20 s, 54 °C for 30 s, and 72 °C for 1 min for 10 cycles and then at 94 °C for 20 s, 54 °C for 30 s, and 72 °C for 4.5 min for the first cycle, with the extension step extended by 30 s for each subsequent cycle, for 25 cycles. At the end of the program, a final extension step at 72 °C for 7 min was performed. PCR products were purified using the Wizard SV Gel and PCR Purification System (Promega), resuspended in 50 µl of water and cloned using the pGEM-T Easy Vector cloning kit (Promega). Colonies were grown overnight at 37 °C with ampicillin selection, and randomly selected colonies were directly PCR amplified using T7 or SP6 primer. For each sample and region, at least ten randomly cloned PCR products were sequenced according to Sanger's method by Eurofins MWG Operon with either SP6 or T7 primer. Sequences were analyzed using BiQ Analyser software 42 , and the average methylation score was calculated as the number of methylated CpGs out of the total number of CpGs in the reference sequence.
Statistics and subjects. The average methylation levels of the groups of samples (patients with FSHD2 carrying an SMCHD1 mutation, control individuals, and patients with BAMS and their relatives) were compared using the KruskalWallis non-parametric multiple-comparisons test followed by a Dunn's comparison and Bonferroni correction, with α = 0.05. Control individuals (n = 8) were healthy donors whom have been previously reported 43 . The patients with FSHD2 carrying an SMCHD1 mutation have previously ben reported 43, 44 and comprise n = 8 with methylation data for the DR1 region and n = 15 each with methylation data for the 5′ and Mid regions, while for the DR1 region 21 additional patients for whom sodium bisulfite sequencing data exist in the LOVD SMCHD1 variant database (see URLs) were included.
Smchd1-Hsp90 structure modeling and multiple-sequence alignment.
A homology model of the N-terminal region of Smchd1 was generated using the online server Phyre2 (ref. 45) . The protein sequence corresponding to amino acids 111-702 of mouse Smchd1 was submitted as the input sequence, and intensive modeling mode was selected. The second highest scoring model with the most sequence alignment coverage based on the crystal structure of yeast Hsp90 (Protein Data Bank (PDB) 2CG9) was elected for further evaluation. The model was visualized in PyMOL. The multiple-sequence alignment was generated using CLUSTAL W (ref. 46 ; via the PBIL server) and ESPript 3.0 (ref. 47 ).
ATPase assays. Cloning, expression and purification of recombinant mouse Smchd1 protein was performed as previously described 22 ; the sequences of the primers used for cloning and mutagenesis are provided in Supplementary  Table 5 . The purity of the protein preparations was assessed by migration of samples on 4-20% Tris-glycine reducing SDS-PAGE gels followed by staining with SimplyBlue SafeStain (Thermo Fisher Scientific) (Supplementary Fig. 13 ). ATPase assays were performed with the Transcreener ADP2 Fluorescence Polarization assay kit (BellBrook Labs) as previously described 22 . Briefly, 10-µl reactions in triplicate were set up in 384-well (low-volume, black) plates, containing 7 µl of reaction buffer (50 mM HEPES (pH 7.5), 4 mM MgCl 2 and 2 mM EGTA), 1 µl of recombinant Smchd1 111-702 protein at concentrations ranging from 0.1 to 0.6 µM or buffer control, 1 µl of radicicol or solvent control, and 1 µl of 10 µM ATP substrate or nuclease-free water control. The Hsp90 inhibitor radicicol (Sigma-Aldrich) was dissolved in 70% ethanol and further diluted to a final concentration ranging from 0.1 nM to 10 µM. A 12-point 10 µM ADP/ATP standard curve was set up in parallel. Reactions were incubated at room temperature for 1 h in the dark before addition of 10 µl of detection mix (1× Stop and Detection Buffer B, 23.6 µg/ml antibody to ADP2) and incubation for a further hour. Fluorescence polarization readings were performed with an Envision plate reader (PerkinElmer Life Sciences) following the manufacturer's instructions. The amount of ADP present in each reaction was estimated using the standard curve, following the manufacturer's instructions.
Mouse embryo dissection and X-gal staining. Mice were housed and mouse work was performed under approval from the Walter and Eliza Hall Institute of Medical Research Animal Ethics Committee (AEC 2014.026). Embryos were obtained by mating C57BL/6 Smchd1 gt/+ congenic strain sires with C57BL/6 dams, with embryo ages ranging from E8.5 to E12.5 (ref. 6 ). All embryos analyzed were female. No randomization or blinding was used during the experimental procedure. Embryos were briefly fixed in 2% paraformaldehyde/0.2% glutaraldehyde and stained in 1 mg/ml X-gal for several hours. Cryosections were cut at 12 µm.
Xenopus embryological assays. Xenopus were used according to guidelines approved by the Singapore National Advisory Committee on Laboratory Animal Research. Protocols for fertilization, injection and whole-mount in situ hybridization are available at the protocol website for the Reversade laboratory (see URLs). Human SMCHD1 (Origene) was cloned into the pCS2+ expression vector, the vector was linearized with NotI and the insert was transcribed with the mMESSAGE mMachine SP6 transcription kit (Thermo Fisher). Transcribed mRNA was column purified, and its concentration was measured using a Nanodrop instrument. The mRNA contains a poly(A) signal that allows for polyadenylation in vivo. To specifically target the cells destined to contribute to anterior head tissue, the two dorsal-animal blastomeres were injected at the eight-cell stage with the synthesized mRNA. Embryos were allowed to develop at room temperature until they reached stages 45-46 (4 d.p.f.) and were fixed. Eye diameter was measured using a Leica stereomicroscope with a DFC 7000T digital camera. No statistical method was used to predetermine sample size. No randomization or blinding was used. Embryos that died before gastrulation were excluded. Injections were performed on multiple clutches to reduce clutch-specific bias. The mRNAs injected for Figure 3k did not contain a poly(A) signal and were polyadenylated in vitro, hence requiring higher RNA concentrations to produce a phenotype (in other panels in Figure 3 and in Supplementary Figure 12 , the mRNAs contained a poly(A) signal allowing polyadenylation in vivo). Embryonic extracts were prepared by lysing stage 12 embryos in CelLytic Express (Sigma) on ice, followed by centrifugation to remove yolk proteins. Extracts were analyzed by immunoblotting with antibodies to SMCHD1 (Atlas, HPA039441; 1:500 dilution) and GAPDH (clone 0411, Santa Cruz Biotechnology; 1:2,000 dilution). cDNA was generated from RNA extracted from Xenopus embryos of various stages using iScript reverse transcriptase (Bio-Rad). qPCR was performed using the primers listed in Supplementary Table 6 . The in situ hybridization probe for smchd1 was amplified from stage 20 cDNA using the primers listed in Supplementary Table 6 and cloned into the pGEM-T vector. The vector was linearized, and the insert was transcribed using digoxigenin RNA labeling mix (Roche) according to the manufacturer's guidelines.
DNA damage response assays. Cell lines and cell culture. XRCC4-deficient cells 48 and primary fibroblast cell lines established from cases 1 and 2 were cultured in DMEM (Gibco) supplemented with 10% FCS (Gibco) and antibiotics. Testing for mycoplasma contamination was negative. To assess H2AX activation, cells were either irradiated with 100 J/m 2 UV-C or treated with 50 µM etoposide (Sigma-Aldrich) for 1 h. Drugs were then washed out, fresh medium was added, and cells were incubated for 6 h and then subjected to immunoblot analysis.
Protein isolation and analysis. Cells were solubilized using ice-cold RIPA buffer (10 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 1 mM Na 3 VO 4 , 10 µM Na 2 MoO 4 , 1% NP-40, 0.25% SDS and protease inhibitors P 2714 (Sigma-Aldrich)). The total protein concentration of extracts was determined using the BCA Protein Assay kit (Thermo Fisher Scientific). Ten micrograms of total cell lysate were separated by 4-12% SDS-PAGE (Invitrogen) and blotted onto nitrocellulose membrane (GE Healthcare). Protein detection was performed using antibody specific for phosphorylation of H2AX at Ser139 (γH2AX) (clone 20E3, Cell Signaling Technology; 1:1,000 dilution). Antibody to β-actin was purchased from Sigma-Aldrich (clone AC-74; 1:10,000 dilution). Secondary antibodies conjugated to peroxidase (Santa Cruz Biotechnology) were used, and blots were developed using an enhanced chemiluminescence system (ECL Plus, GE Healthcare), followed by detection of autoradiography by film.
Microhomology-mediated end joining assay. Microhomology-mediated end joining (MMEJ) assays using linearized pDVG94 plasmid were performed as previously described 49 . In brief, cells were transfected with 2 µg of pDVG94 linearized with EcoRV (Thermo Fisher Scientific) and AfeI (New England BioLabs), and extrachromosomal DNA was isolated 48 h after transfection. PCR analysis was performed, and PCR products were digested using BstXI, separated by gel electrophoresis and visualized by ethidium bromide staining.
Data availability. Whole-exome sequencing data have been deposited in the European Genome-phenome Archive (EGA) under accessions EGAS00001002193.
